Table 3 Basic information of the participants (N = 396)
Variable | Control | Intervention | P-value* | |
|---|---|---|---|---|
n = 198 | n = 198 | |||
Gender,n(%) | 0.510 | |||
Male | 108(54.5) | 101(51.0) | ||
female | 90(45.5) | 97(49.0) | ||
Gender, mean (SD) | 1.45(0.50) | 1.49(0.50) | ||
Age,n(%) | 0.399 | |||
60–64 | 51(25.8) | 55(27.8) | ||
65–69 | 89(44.9) | 71(35.9) | ||
70–74 | 55(27.8) | 64(32.3) | ||
≥ 75 | 3(1.5) | 8 (4) | ||
Clinical Features,n(%) | ||||
Hypertension | 36(18.2) | 44(22.2) | 0.317 | |
Hypercholesterolemia | 13(6.6) | 23(11.6) | 0.081 | |
Diabetes | 17(8.6) | 25(12.6) | 0.192 | |
Heart disease | 10(5.1) | 18(9.1) | 0.117 | |
Stroke | 5(2.5) | 11(5.6) | 0.126 | |
Chronic lung disease | 27(13.6) | 32(16.2) | 0.481 | |
Fall in the past year | 42(21.2) | 49(24.7) | 0.404 | |
Hip fracture in the past year | 5(2.5) | 4(2.0) | 0.736 | |
Non-femoral fracture in the past year | 29(14.6) | 34(17.2) | 0.493 | |
≥ 5 medications at screening | 8(4.0) | 16(8.1) | 0.092 | |